JP2022553421A5 - - Google Patents
Info
- Publication number
- JP2022553421A5 JP2022553421A5 JP2022524928A JP2022524928A JP2022553421A5 JP 2022553421 A5 JP2022553421 A5 JP 2022553421A5 JP 2022524928 A JP2022524928 A JP 2022524928A JP 2022524928 A JP2022524928 A JP 2022524928A JP 2022553421 A5 JP2022553421 A5 JP 2022553421A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutical composition
- chemotherapeutic agents
- compound
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926963P | 2019-10-28 | 2019-10-28 | |
| US62/926,963 | 2019-10-28 | ||
| PCT/IB2020/060104 WO2021084441A2 (en) | 2019-10-28 | 2020-10-28 | Methods and compositions for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553421A JP2022553421A (ja) | 2022-12-22 |
| JP2022553421A5 true JP2022553421A5 (https=) | 2023-11-07 |
Family
ID=75714907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524928A Pending JP2022553421A (ja) | 2019-10-28 | 2020-10-28 | がんの処置のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220370397A1 (https=) |
| EP (1) | EP4051260A4 (https=) |
| JP (1) | JP2022553421A (https=) |
| KR (1) | KR20220114532A (https=) |
| CN (1) | CN114650815A (https=) |
| WO (1) | WO2021084441A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020144538A1 (en) * | 2019-01-07 | 2020-07-16 | Enzychem Lifesciences Corporation | Compositions and methods for modulating an inflammatory response |
| US20220125882A1 (en) * | 2019-01-16 | 2022-04-28 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100283010B1 (ko) * | 1997-11-20 | 2001-04-02 | 전길자 | 녹용 추출물을 함유하는 조혈모세포 및 혈소판 전구세포 증식촉진용 조성물 |
| KR20050118057A (ko) * | 2004-04-24 | 2005-12-15 | 김상희 | 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품 |
| CA2562897C (en) * | 2004-04-24 | 2011-03-15 | Sang-Hee Kim | Immunomodulating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives |
| EP3037092B1 (en) * | 2013-08-19 | 2020-01-01 | Enzychem Lifesciences Corporation | Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer |
| JP6321886B2 (ja) * | 2014-05-15 | 2018-05-09 | エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | 白血球減少症及び血小板減少症に対する治療方法 |
| AU2016226157B2 (en) * | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
| EP3400218A4 (en) * | 2016-01-08 | 2019-09-18 | Euclises Pharmaceuticals, Inc. | COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE |
| JP7194022B2 (ja) * | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| WO2018029124A1 (en) * | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| KR20190063536A (ko) * | 2017-11-30 | 2019-06-10 | 주식회사 엔지켐생명과학 | 1-팔미토일-2-리놀레오일-3-아세틸글리세롤을 포함하는 급성 방사선 증후군의 예방 또는 치료용 조성물 |
| US20220125882A1 (en) * | 2019-01-16 | 2022-04-28 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
-
2020
- 2020-10-28 JP JP2022524928A patent/JP2022553421A/ja active Pending
- 2020-10-28 KR KR1020227017330A patent/KR20220114532A/ko not_active Ceased
- 2020-10-28 EP EP20882109.0A patent/EP4051260A4/en active Pending
- 2020-10-28 US US17/770,990 patent/US20220370397A1/en active Pending
- 2020-10-28 CN CN202080076324.7A patent/CN114650815A/zh active Pending
- 2020-10-28 WO PCT/IB2020/060104 patent/WO2021084441A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006501176A5 (https=) | ||
| JP2022553421A5 (https=) | ||
| JP2021063088A5 (https=) | ||
| JP2019519467A5 (https=) | ||
| JP2008543854A5 (https=) | ||
| JP2009536221A5 (https=) | ||
| JP2003515558A5 (https=) | ||
| JPH02300139A (ja) | 不飽和脂肪酸投与により癌の治療を増強させる方法 | |
| JP2019510004A5 (https=) | ||
| JP2006505543A5 (https=) | ||
| CA2410311A1 (en) | Barbituric acid analogs as therapeutic agents | |
| JP2005533835A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2015508103A5 (https=) | ||
| AU2017258304B2 (en) | 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases | |
| AU2020374961A1 (en) | Methods of treating cancer in biomarker-identified patients with inhibitors of cyclin-dependent kinase 7 (CDK7) | |
| JP2011506274A5 (https=) | ||
| JP5149177B2 (ja) | 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤 | |
| JP2007505044A5 (https=) | ||
| JP2018525425A5 (https=) | ||
| JP2018534256A5 (https=) | ||
| JP2024502178A5 (https=) | ||
| JP2022547331A5 (https=) | ||
| EP0095663B1 (en) | Organic selenium compounds having an anti-neoplastic activity | |
| JP2023510797A5 (https=) |